Disease relevance of CLEC12A

• DCAL-2 may be a potential immunotherapeutic target for modulating autoimmune diseases or for developing vaccines [1].
• Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1) [2].

High impact information on CLEC12A

• DCAL-2 is a CLR with a cytosolic immunoreceptor tyrosine-based inhibitory motif (ITIM), which is restricted to immature DCs (iDCs), monocytes, and CD1a+ DCs [1].
• Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production [1].
• Cross-linking DCAL-2 on iDCs induced protein tyrosine phosphorylation and MAPK activation as well as receptor internalization [1].
• Thus, DCAL-2 may program DCs differently depending on whether DCs are signaled via TLRs or by T cells [1].
• Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes [3].

Biological context of CLEC12A

• Although MICL was highly N-glycosylated in primary cells, the level of glycosylation was found to vary between cell types [4].

Anatomical context of CLEC12A

• This suggests that human MICL may be involved in the control of myeloid cell activation during inflammation [4].

References